Scalper1 News
Specialty drugmaker Sucampo Pharmaceuticals (SCMP) was up more than 6% Friday following a volatile week of trading, after the company’s lead drug was granted accelerated review by the FDA. Late Thursday, Sucampo said the FDA had granted its drug candidate cobiprostone fast-track designation as a treatment for oral mucositis, or inflammation of the mucus membranes in the mouth. The company still has a ways to go to get it on the market, though, as Scalper1 News
Scalper1 News